Haemophilus influenzae type A glycoconjugate vaccine - InventVacc Biologicals
Alternative Names: HIA vaccine - InventVacc BiologicalsLatest Information Update: 03 Jul 2024
At a glance
- Originator National Research Council Canada; Public Health Agency of Canada
- Developer InventVacc Biologicals
- Class Glycoconjugates; Haemophilus vaccines; Influenza A vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Haemophilus infections
Most Recent Events
- 29 May 2024 Phase-I clinical trials in Haemophilus infections (Prevention) in Canada (IM) (NCT06465420)